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MicroRNAs are widely dysregulated in various cancers and integrated into tumorigenic programs as
either oncogenes or tumor suppressor genes. Here, we show that miR-26b, which is down-regulated
in human breast cancer specimens and cell lines, impairs viability and triggers apoptosis of human
breast cancer MCF7 cells. SLC7A11 is identiﬁed as a direct target of miR-26b and its expression is
remarkably increased in both breast cancer cell lines and clinical samples. Furthermore, SLC7A11
silence mimics miR-26b-aroused viability impairment and apoptosis in MCF7 cells. Our studies
reveal a protective role of miR-26b in the molecular etiology of human breast cancer by promoting
apoptosis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction ciated with poor prognosis [4]. However, the mechanism by whichMicroRNAs are composed of 22 nucleotides and predomi-
nantly perform negative regulation of gene expression throughout
complementarity with the 30 untranslated regions (30-UTRs) of
mRNAs [1]. Attributed to its multiple targets, one microRNA may
present with diverse functions. In humanmalignancies, microRNAs
undergo nearly ubiquitous dysregulation and broadly regulate cell
proliferation, apoptosis and differentiation [2]. MicroRNAs can
function as oncogenes or tumor suppressors and contribute to
tumorigenesis by their targets [3]. Recent studies indicate that
miR-26b is down-regulated in hepatocellular carcinoma [4], naso-
pharyngeal carcinomas [5], primary squamous cell lung carcino-
mas [6] and squamous cell carcinoma of tongue [7]. Furthermore,
the down-regulated miR-26b endows normal liver tissue to devel-
op hepatocellular carcinoma-promoting inﬂammation and is asso-chemical Societies. Published by E
rtment of Pathophysiology,
. 280, Chong-Qing South Rd,
hao). Department of General
sity School of Medicine, No.
e).
He), qzhao@shsmu.edu.cnmiR-26b regulates tumorigenesis is unclear.
Dysregulated microRNAs contribute to neoplastic transforma-
tion by their targets. Solute carrier family seven member eleven
(SLC7A11) is a subunit of the amino acid transport system xc that
mediates the entry of cystine into cells in exchange for glutamate
[8,9]. The xc system contributes to develop cisplatin resistance in
ovarian cancer cells [10]. Moreover, SLC7A11 protects cancer cells
of the NCI-60 panel from chemoresistance to numerous com-
pounds [11]. Therefore, SLC7A11 would play an important role in
conveying resistance to apoptosis in distinct cells.
In this study we ﬁrst revealed that miR-26b is down-regulated
in human breast cancer cell lines and clinical samples and its over-
expression induces cell apoptosis and targets SLC7A11 in MCF7
cells. These results indicated that reduced expression of miR-26b
facilitates the development of human breast cancer.
2. Materials and methods
2.1. Constructs
The 3971 bp truncated 30-UTR of SLC7A11 was ampliﬁed using
primers SLC7A11-UTR-F/R (Supplementary Table S1) and then
cloned into the downstream of the ﬁreﬂy luciferase gene in thelsevier B.V. All rights reserved.
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gene, La Jolla, CA) was utilized to separately introduce three or four
mutated bases into four predicted miR-26b binding-sites using
speciﬁc primers (Table S1).
2.2. Evaluation of cell viability
A total of 3.0  103 CCD-1095Sk, 3.5  103 MCF7, 8.0  103
HCC1937 or 8.5  103 MDA-MB-231 cells were mixed with
15 pmol microRNA mimics together with 0.375 ll Lipofectamine
2000 (Invitrogen, Paisley, Scotland, UK) and then inoculated in
each pore of 96-well plates. After 20 h of incubation, 100 ll fresh
medium was applied for these cells. In each well, the cells and
10 ll Cell Counting Kit-8 (CCK-8) (Dojindo, Kumamoto, Japan)
were together incubated for 2 h at 37 C and their optical density
at 450 nm was detected in a microplate reader.
2.3. Apoptosis assay
Apoptosis was detected by the terminal deoxynucleotidyl trans-
ferase (TdT)-mediated deoxyuridine triphosphate (dUTP) nick end-
labeling (TUNEL) assay with an in situ cell death detection kit
(Roche, Basel, Switzerland). The MCF7 cells transfected with
100 nM negative control (NC) or miR-26b mimics were subjected
to TUNEL assay at 24, 48, 72 and 96 h. Furthermore, the localiza-
tion of phosphatidylserine residues were identiﬁed by Annexin
V/propidium iodide (PI) staining (BD Biosciences Pharmingen,
San Diego, CA).
2.4. Statistical analysis
Data are presented as mean ± standard deviation (S.D.). The
two-tailed t-test was used to draw a comparison between groups.
Differences are considered as signiﬁcant when the P value is under
0.05.
3. Results
3.1. Expression of miR-26b is decreased in human breast cancer
We ﬁrst determined the expression level of miR-26b in breast
cancer tissues and cell lines by real-time RT-PCR. The relative
expression level of miR-26b was separately shown for all clinical
patients (Table S2). Moreover, 25 of 27 patients show decreased
expression of miR-26b in breast cancer tissues versus paired nor-
mal adjacent tissues (P < 0.001) (Fig. 1A). Interestingly, the expres-
sion level of miR-26b is signiﬁcantly associated with HER2 status
among clinical pathological parameters (P = 0.04) (Table S3). We
further detected the abundance of miR-26b in seven human breast
cancer cell lines, MCF7, HCC1937, MDA-MB-231, MDA-MB-468,
MDA-MB-453, BT-549 and BT-474. Compared with the normal
breast skin cells CCD-1095Sk, the above seven breast cancer cell
lines show signiﬁcant decrease in miR-26b expression (Fig. 1B).
These results indicated that the expression of miR-26b is signiﬁ-
cantly decreased in human breast cancer specimens and cell lines.
3.2. MiR-26b impairs viability of partial breast cancer cells
CCD-1095Sk, MCF7, MDA-MB-231 and HCC1937 cells were
respectively transfected with NC or miR-26b mimics and subjected
to viability analysis at 24, 48, 72 and 96 h. The viability of CCD-
1095Sk cells was only slightly affected by over-expressed
miR-26b (Fig. 2A), but miR-26b-transfected MCF7 cells underwent
viability decrease by 31% and 30% relative to NC at 72 and 96 h,
respectively (Fig. 2B). Moreover, over-expressed miR-26b sup-pressed the viability of HCC1937 cells more signiﬁcantly than
MCF7 cells (Fig. S1A). However, miR-26b did no harm to the viabil-
ity of MDA-MB-231 cells (Fig. S1B). In addition, MCF7 cells indicate
a major type of human clinical breast cancer [12], so we choose
this cell line for further study. These data indicate that miR-26b
suppresses the viability of partial human breast cancer cells but
does little harm to the growth of normal cells, which hints great
medicinal values of miR-26b in the treatment of human breast
cancer.
3.3. GO analysis
A total of 5300 binding-sites in all human gene transcripts were
predicted as putative miR-26b targets by miRanda. Through GO
annotation, we further assigned these predicted targets to 1962
categories. Under the criteria of P < 1.0  105 and FDR < 1.0 
103, 40 GO categories are presented according to their P-values
(Fig. S2). Combining with our observation that over-expressed
miR-26b attenuates viability of MCF7 cells, we pay more attention
to the GO category ‘‘negative regulation of apoptosis’’
(P = 5.01  1012, FDR = 6.32  1010) which ranked the second
top among all categories. Therefore, we try to investigate whether
over-expressed miR-26b can trigger apoptosis of MCF7 cells.
3.4. MiR-26b induces apoptosis of MCF7 cells
Besides viability impairment, MCF7 cells transfected with miR-
26b showed aberrant morphologic features, such as blurred edges,
blebbing, scattered cell debris and detachment from matrix
(Fig. 2C). These phenomena were also observed in miR-26b-tran-
fected HCC1937 cells but not in human normal breast skin
CCD1095Sk cells. To investigate whether miR-26b can induce
apoptosis of MCF7 cells, we performed Annexin V/PI staining and
TUNEL assay, respectively. Consequently, the fraction of apoptotic
MCF7 cells persistently increased from 72 h to 96 h (Fig. 2D/E
and Supplementary Fig. S3A/B).
Furthermore, we detected the change of caspase-8, caspase-9
and PARP-1 by Western Blot. Four activated fragments (p43, p41,
p26, and p24) of caspase-8 and a 37 kD auto-cleaved band of cas-
pase-9 were clearly observed in MCF7 cells at 96 h after miR-26b
treatment (Fig. 2F). Additionally, PARP-1 was partly cleaved to
89 kD fragment in miR-26b over-expressed cells at 96 h (Fig. 2F).
The above results provided extensive evidence that cells under-
went apoptosis. Therefore, over-expression of miR-26b can effec-
tively initiate apoptosis of MCF7 cells.
3.5. SLC7A11 is a direct target of miR-26b
SLC7A11, one of predicted miR-26b targets, conveys anti-apop-
totic effect in multiple cancer cells. The SLC7A11 30-UTR contains
four miR-26b matching-sites with two conserved and two poorly
conserved across mammals (Fig. 3A). The four potential miR-26b
binding-sites are respectively located in the downstream
4128  4148 (CS1), 4688  4708 (NS1), 5230  5250 (NS2) and
7793  7813 nt (CS2) from the 50 end of the SLC7A11 30-UTR
(Fig. 3A and Supplementary Fig. 4). The 3971 bp amplicon with
the above four binding sites was isolated and cloned into the repor-
ter pMIR-REPORT. Subsequently, the constructs were transiently
transfected into HEK293T cells along with NC or miR-26b mimics
and relative luciferase activity was measured at 24 h. The relative
luciferase activity of the construct with wild-type 30-UTR was
signiﬁcantly repressed by 54% following miR-26b transfection
(Fig. 3B). Moreover, the repression of relative luciferase activity
was obviously attenuated when two conserved sites CS1 and CS2
were mutated respectively or jointly (Fig. 3B). However, disruption
of two non-conserved sites NS1 and NS2 failed to restore any
Fig. 1. Down-regulation of miR-26b in clinical samples and cell lines of human breast cancer. (A) Comparison of the miR-26b abundance in paired human breast tumors and
adjacent normal tissues. The solid squares represent the relative expression level of miR-26b. The miR-26b abundance for each paired non-tumor and tumor tissues were
separately shown in the left and right parts and connected by a dash line. (B) The expression difference of miR-26b in CCD-1095Sk and seven breast cancer cell lines. ‘‘#’’
(P < 0.01) represents great signiﬁcant difference by a two-tailed Student’s t-test.
Fig. 2. Over-expression of miR-26b attenuates viability and induces apoptosis of MCF7 cells. (A and B) Effects of over-expressed miR-26b on the viability of CCD-1095Sk and
MCF7 cells. (C) Morphological characteristics of MCF7 cells at 96 h post transfection of NC or miR-26b mimics. (D) Apoptosis detection for MCF7 cells by Annexin V/PI
staining. The proportion of Annexin V positive cells is shown in the y-axis. (E) TUNEL assay for MCF7 cells following transfection of NC or miR-26b mimics. ‘‘#’’ (P < 0.01)
represents great signiﬁcant difference by a two-tailed Student’s t-test for panels A, B, D and E. (F) Detection of caspase-8/9 and PARP-1 in MCF7 cells at 48 and 96 h after
transfection of NC or miR-26b mimics. ‘‘D’’ means cleaved fragments.
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SLC7A11 expression by binding CS1 and CS2 in the SLC7A11 30-
UTR. Moreover, the relative luciferase activity from the reporter
with wild-type 30-UTR was signiﬁcantly increased to 1.7 fold due
to the application of miR-26b inhibitors (Fig. 3C).
Compared with NC, miR-26b obviously represses the expression
of endogeneous SLC7A11 at 48 h after transfection (Fig. 3D). In con-
trast, miR-26b inhibitors signiﬁcantly enhances the expression of
SLC7A11 compared with negative control inhibitors (Fig. 3D).
Moreover, there is higher amount of SLC7A11 in all seven breast
cancer cell lines than CCD1095Sk cells (Fig. 3E). On the contrary,
miR-26b in all seven breast cancer cell lines has a lower expression
than that of CCD1095Sk cells (Fig. 1B). Generally, the intensity ofSLC7A11 was inversely correlated with the abundance of miR-
26b in CCD1095Sk and seven breast cancer cell lines (Fig. 3E and
Supplementary Fig. S5B). Similarly, the inverse correlation is also
observed in clinical breast cancer samples (Fig. 3F and Supplemen-
tary Fig. S5A). All these data support that SLC7A11 is a direct target
of miR-26b.
3.6. SLC7A11 silence mimics miR-26b-aroused effects in MCF7 cells
Viability and apoptosis of MCF7 cells were evaluated following
application of siRNA against SLC7A11. Compared with negative
control (siLuciferase), pooled siSLC7A11-transfected MCF7 cells
show a signiﬁcant suppression of SLC7A11 expression at 48 h
Fig. 3. SLC7A11 is a direct target of miR-26b. (A) Diagram of the SLC7A11 30-UTR with potential binding-sites of miR-26b. (B) Relative luciferase activity of reporters including
wild-type or mutant SLC7A11 30-UTR with cotransfected NC or miR-26b mimics. ‘‘CS1mut’’, ‘‘CS2mut’’, ‘‘NS1mut’’ and ‘‘NS2mut,’’ respectively indicate mutations of the above
four binding-sites while ‘‘SS12mut’’ means mutations of both CS1 and CS2 sites. (C) Relative luciferase activity of reporters including the wild-type SLC7A11 30-UTR with
cotransfected negative control inhibitor (NCi) or miR-26b inhibitors (miR-26bi). ‘‘⁄’’ denotes P < 0.05 while ‘‘#’’ means P < 0.01 following a two-tailed Student’s t-test for panels
B and C. (D) Expression of endogenous SLC7A11 in MCF7 cells subjected to miR-26b over-expression or knockdown. b-Actin was loaded as an internal control. (E) Expression
of SLC7A11 in CCD-1095Sk and seven breast cancer cell lines. ‘‘⁄’’ means non-speciﬁc bands. (F) Expression of SLC7A11 in six paired clinical breast cancer samples. T and N
mean breast cancer tissues and paired adjacent normal tissues, respectively. Vinculin was used as an internal control.
Fig. 4. SLC7A11 knockdown results in viability impairment and apoptosis of MCF7 cells. (A) Expression of endogenous SLC7A11 in MCF7 cells transfected with siLuciferase or
pooled siSLC7A11. (B) Viability of MCF7 cells transfected with siLuciferase or pooled siSLC7A11 at 24, 48, 72 and 96 h. (C) TUNEL assay of control and SLC7A11-silenced MCF7
cells. In the left panel, the cellular nuclei and apoptotic cells appeared with blue or green colors, respectively. Quantitative analysis of TUNEL-positive cells is shown in the
right panel. ‘‘⁄’’ (P < 0.05) and ‘‘#’’ (P < 0.01) separately mean signiﬁcant and great signiﬁcant difference following a two-tailed Student’s t-test.
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the optical density at 450 nm at 24, 48, 72 and 96 h. Relative to
siLuciferase, pooled siSLC7A11-mediated SLC7A11 silence signiﬁ-
cantly suppressed cell viability by 15%, 29%, 42% and 30% at 24,
48, 72 and 96 h, respectively (Fig. 4B). Then, we further evaluated
cell apoptosis by TUNEL assay at each 24 h time-point for both
siLuciferase and pooled siSLC7A11 treated MCF7 cells in four days.
Consequently, SLC7A11 silence promotes 21% MCF7 cells apoptosis
at 72 and the apoptosis fraction was persistently increased and
reached as high as 31% at 96 h after transfection (Fig. 4C).
4. Discussion
One microRNA can perform pleiotropical functions by regulat-
ing multiple targets [13,14]. We validated SLC7A11 as a direct tar-
get of miR-26b in MCF7 cells. Generally, the expression level of
miR-26b is inversely correlated with that of SLC7A11 in clinical
specimens and seven human breast cancer cell lines. Therefore,
down-regulation of miR-26b may contribute to the increased
expression of SLC7A11. SLC7A11 and solute carrier family three
member two (SLC3A2) constitute a glutamate–cystine antiporter
xc which mediates the pancreatic cancer growth and drug resis-
tance [8,15]. Moreover, the death of ﬁbroblasts and melanocytes
from Sut mutant mouse with SLC7A11 silence is caused by apopto-
sis [16,17]. Our wok showed that SLC7A11 silence can impair via-
bility and induce apoptosis of MCF7 cells. Therefore, we may
reasonably speculate that SLC7A11 would contribute to miR-26b-
mediated apoptosis in MCF7 cells.
Other genes directly regulated by miR-26b may contribute to
breast carcinogenesis. The expression level of growth hormone
negatively responses to miR-26b by its target lymphoid enhan-
cer-binding factor 1 (LEF-1) in rat pituitary tumor GH3 cells [18].
Additionally, over-expression of miR-26b inhibits proliferation of
carcinoma of nasopharyngeal epithelial (CNE) cells by targeting
cyclooxygenase-2 (COX-2) which conveys resistance to apoptosis
[5]. Additionally, there is a consistency for the forward 10 bases
from the 50 terminus of miR-26a and miR-26b. Both microRNAs
probably share a set of targets because perfect seed pairing is cru-
cial for prediction reliability [19]. To date, several apoptosis-
related proteins have been identiﬁed as miR-26a targets, such as
cyclin D2 (CCND2), cyclin E2 (CCNE2) and AEG1 [20,21]. Therefore,
it is necessary to investigate whether miR-26b mediated apoptosis
is partly ascribed to these identiﬁed targets.
Collectively, our ﬁndings suggest that miR-26b can promote
apoptosis of MCF7 cells and directly regulates the expression of
SLC7A11. Moreover, SLC7A11 is signiﬁcantly up-regulated in both
clinical specimens and cell lines of breast cancer. Our study re-
vealed the pathological role of miR-26b and its potential applica-
tion in breast cancer treatment.
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